Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  monoclonal antibody conjugate
Results 1-25 of 1842 for your search:
Start Over
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: XMT-1522-1, NCI-2017-00221, NCT02952729
Chimeric Fibril-Reactive Monoclonal Antibody 111F4 in Treating Patients with Relapsed or Refractory Amyloid Light-Chain Amyloidosis
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: AAAM5108, NCI-2014-01515, IRB-AAAM5108, NCT02245867
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 99
Trial IDs: M15-394, NCI-2016-00469, 2015-001645-84, NCT02565758
A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-237, NCI-2014-00926, 2014-003154-14, NCT02099058
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: EC1456-01, NCI-2016-00552, NCT01999738
HuMax-AXL-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GCT1021-01, NCI-2017-00143, NCT02988817
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SGNLVA-001, NCI-2013-02245, NCT01969643
Conjugated Estrogens/Bazedoxifene in Treating Patients with Ductal Carcinoma in Situ Undergoing Surgery
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: NU 15B06, NCI-2016-00066, STU00202100, NCT02694809
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CDX011-05, NCI-2015-00448, NCT02302339
Glembatumumab Vedotin in Treating Patients with Metastatic or Locally Recurrent Uveal Melanoma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9855, NCI-2015-00159, NCI9855, NCT02363283
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PrE0504, NCI-2016-00523, CDX011-54, NCT02713828
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GEN702, NCI-2015-01770, NCT02552121
Bendamustine Hydrochloride and Dexamethasone in Treating Patients with Relapsed Amyloidosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAJ7800, NCI-2012-00896, NCT01222260
Study in Subjects With Light Chain (AL) Amyloidosis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NEOD001-OLE251, NCI-2017-01058, NCT03154047
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Status: Enrolling by invitation
Phase: Phase III
Type: Treatment
Age: 18 to 85
Trial IDs: ALN-TTR02-006, NCI-2017-00574, NCT02510261
Ibrutinib with or without Bortezomib and Dexamethasone in Treating Patients with Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1687, NCI-2017-00660, NCT03130348
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: ADCT-402-102, NCI-2016-00226, NCT02669264
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX014-01, NCI-2016-01448, NCT02837991
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C16011, NCI-2012-02752, 2011-005468-10, C16011-CTIL, NL41603.028.12, U1111-1164-7621, NCT01659658
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SGN19B-001, NCI-2016-00414, NCT02702141
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15383, NCI-2015-01621, I7O-MC-JOBA, NCT02529553
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 74
Trial IDs: SGN123-001, NCI-2016-01475, NCT02848248
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Untreated Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma or Gray Zone Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 17413, NCI-2013-02359, 818280, NCT01994850
Brentuximab Vedotin in Treating Patients with Advanced Systemic Mastocytosis or Mast Cell Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HEMMPD0016, NCI-2013-00537, 25727, NCT01807598
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-010, NCI-2010-02267, 2010-020363-21, NCT01196208
Start Over